Cite
MLA Citation
S Pintar et al.. “P702 Clinical and biomarker remission is maintained after switch from monthly dosed intravenous to subcutaneous maintenance treatment with vedolizumab in Inflammatory Bowel Disease.” Journal of Crohn's and colitis, vol. 17, n.d., pp. i834–i835. http://access.bl.uk/ark:/81055/vdc_100179844252.0x000036